Latest News

Teva Announces Changes to Executive Management Team

Teva Announces Changes to Executive Management Team

Teva to Present at the 21st Annual Morgan Stanley Global Healthcare Conference

Teva to Present at the 21st Annual Morgan Stanley Global Healthcare Conference

Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetra...

Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenaz

Teva Settles Price Fixing Charges With U.S. DOJ

Teva Settles Price Fixing Charges With U.S. DOJ

Teva Reports Second Quarter 2023 Financial Results

Teva Reports Second Quarter 2023 Financial Results

Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development

Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development

Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership

Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership

Teva to Host Conference Call to Discuss Second Quarter 2023 Financial Results at 8 a.m. ET on August...

Teva to Host Conference Call to Discuss Second Quarter 2023 Financial Results at 8 a.m. ET on August 2, 2

Teva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab) reveals sustained lon...

Teva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab) reveals sustained long-ter

Teva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating A...

Teva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY®

Teva Reaches Agreement With Kentucky to Settle the State’s Price Fixing Claims

Teva Reaches Agreement With Kentucky to Settle the State’s Price Fixing Claims

Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®

Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®

Teva Concludes Nationwide Opioids Settlement Agreement

Teva Concludes Nationwide Opioids Settlement Agreement

Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration ...

Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit a

Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Signi...

Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significan

Teva Launches New “Pivot to Growth” Strategy

Teva Launches New “Pivot to Growth” Strategy

AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, New Once-Daily Formulation of AUSTEDO®, Now...

AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, New Once-Daily Formulation of AUSTEDO®, Now Avai

Teva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP Outlook

Teva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP Outlook

Teva Shares Progress Toward Access to Medicines and Environmental Commitments, Meeting and Exceeding...

Teva Shares Progress Toward Access to Medicines and Environmental Commitments, Meeting and Exceeding Seve

U.S. Mental Health Access Program Expands Medicine Donation to Seven New States

U.S. Mental Health Access Program Expands Medicine Donation to Seven New States

Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspens...

Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension,

Teva to Launch New Growth Strategy at Investor Day

Teva to Launch New Growth Strategy at Investor Day

Teva to Host Conference Call to Discuss First Quarter 2023 Financial Results at 8 a.m. ET on May 10,...

Teva to Host Conference Call to Discuss First Quarter 2023 Financial Results at 8 a.m. ET on May 10, 2023

Complete Response Letter Received for AVT02 Biologics License Application

Complete Response Letter Received for AVT02 Biologics License Application

Teva to Present New Data on Once-Daily AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets at th...

Teva to Present New Data on Once-Daily AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets at the 202

Teva’s Digital Health Collaboration with Rimidi Expands to Include Respiratory Monitoring Program In...

Teva’s Digital Health Collaboration with Rimidi Expands to Include Respiratory Monitoring Program Integra

Teva Announces Early Tender Results of its Debt Tender Offer, Increases to Tender Caps and Election ...

Teva Announces Early Tender Results of its Debt Tender Offer, Increases to Tender Caps and Election of Ea

Teva and Natco Announce Launch of additional strengths for the Generic Version of Revlimid® (lenalid...

Teva and Natco Announce Launch of additional strengths for the Generic Version of Revlimid® (lenalidomide

Teva to Present at the Barclays Global Healthcare Conference

Teva to Present at the Barclays Global Healthcare Conference

Teva Announces Successful Upsize and Pricing of $2,490,000,000 (equivalent) Sustainability-Linked Se...

Teva Announces Successful Upsize and Pricing of $2,490,000,000 (equivalent) Sustainability-Linked Senior

Teva Announces Launch of $2,060,000,000 (Equivalent) Offering of Sustainability-Linked Senior Notes

Teva Announces Launch of $2,060,000,000 (Equivalent) Offering of Sustainability-Linked Senior Notes

Teva Announces $2,250,000,000 Debt Tender Offers for Notes Due 2023-2026

Teva Announces $2,250,000,000 Debt Tender Offers for Notes Due 2023-2026

Teva to Present New Data from CONNECT2 Study on its Digihaler® System at the American Academy of All...

Teva to Present New Data from CONNECT2 Study on its Digihaler® System at the American Academy of Allergy,

Teva Announces Publication of New Clinician Scale in Journal of Clinical Psychiatry to Assess the Im...

Teva Announces Publication of New Clinician Scale in Journal of Clinical Psychiatry to Assess the Impact

Teva Announces FDA Approval of AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, a New Once-D...

Teva Announces FDA Approval of AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily

Teva Reaches Agreement With Florida to Settle the State’s Price Fixing Claims

Teva Reaches Agreement With Florida to Settle the State’s Price Fixing Claims

Teva Reports Fourth Quarter and Full Year 2022 Financial Results

Teva Reports Fourth Quarter and Full Year 2022 Financial Results

Teva’s Ambitious Climate Targets Externally Validated by the Science Based Targets initiative (SBTi)

Teva’s Ambitious Climate Targets Externally Validated by the Science Based Targets initiative (SBTi)

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and 2023...

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and 2023 Fina

Teva Announces Nationwide Opioids Settlement to Move Forward After Receiving Broad Support from Stat...

Teva Announces Nationwide Opioids Settlement to Move Forward After Receiving Broad Support from States

Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Bi...

Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimi

Teva to Present at the 41st Annual J.P. Morgan Healthcare Conference

Teva to Present at the 41st Annual J.P. Morgan Healthcare Conference